Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

COMPASS Pathways Plc (CMPS) — LONDON & NEW YORK, August 06, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumat

Source: Business Wire — read the full announcement there.

See our COMPASS Pathways company profile for background, links, and more COMPASS Pathways news.